These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 29145934)

  • 41. The INTRABEAM® Photon Radiotherapy System for the adjuvant treatment of early breast cancer: a systematic review and economic evaluation.
    Picot J; Copley V; Colquitt JL; Kalita N; Hartwell D; Bryant J
    Health Technol Assess; 2015 Aug; 19(69):1-190. PubMed ID: 26323045
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Systematic mapping review about costs and economic evaluations of skin conditions and diseases in the aged.
    Lichterfeld-Kottner A; Hahnel E; Blume-Peytavi U; Kottner J
    J Tissue Viability; 2017 Feb; 26(1):6-19. PubMed ID: 27544020
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Economic evaluations of treatments for systemic fungal infections: a systematic review of the literature.
    Dixon S; McKeen E; Tabberer M; Paisley S
    Pharmacoeconomics; 2004; 22(7):421-33. PubMed ID: 15137881
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cost of Tuberculosis Diagnosis and Treatment in Patients with HIV: A Systematic Literature Review.
    de Siqueira-Filha NT; Legood R; Cavalcanti A; Santos AC
    Value Health; 2018 Apr; 21(4):482-490. PubMed ID: 29680106
    [TBL] [Abstract][Full Text] [Related]  

  • 45. What is the clinical effectiveness and cost-effectiveness of conservative interventions for tendinopathy? An overview of systematic reviews of clinical effectiveness and systematic review of economic evaluations.
    Long L; Briscoe S; Cooper C; Hyde C; Crathorne L
    Health Technol Assess; 2015 Jan; 19(8):1-134. PubMed ID: 25629427
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Systematic Review of Economic Evaluations of Units Dedicated to Acute Coronary Syndromes.
    Azeredo-Da-Silva AL; Perini S; Rigotti Soares PH; Polaczyk CA
    Value Health; 2016; 19(2):286-95. PubMed ID: 27021764
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Economic impact of electronic prescribing in the hospital setting: A systematic review.
    Ahmed Z; Barber N; Jani Y; Garfield S; Franklin BD
    Int J Med Inform; 2016 Apr; 88():1-7. PubMed ID: 26878756
    [TBL] [Abstract][Full Text] [Related]  

  • 48. What do we know about managing Dupuytren's disease cost-effectively?
    Dritsaki M; Rivero-Arias O; Gray A; Ball C; Nanchahal J
    BMC Musculoskelet Disord; 2018 Jan; 19(1):34. PubMed ID: 29370792
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer treatment-induced anaemia (including review of technology appraisal no. 142): a systematic review and economic model.
    Crathorne L; Huxley N; Haasova M; Snowsill T; Jones-Hughes T; Hoyle M; Briscoe S; Coelho H; Long L; Medina-Lara A; Mujica-Mota R; Napier M; Hyde C
    Health Technol Assess; 2016 Feb; 20(13):1-588, v-vi. PubMed ID: 26907163
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Health economic evaluations based on routine data in Germany: a systematic review.
    Gansen FM
    BMC Health Serv Res; 2018 Apr; 18(1):268. PubMed ID: 29636046
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antibiotic misuse: How to evaluate the costs?
    Silva ML; Cargnello C; Aulois-Griot M; Dumartin C
    Med Mal Infect; 2019 Oct; 49(7):485-494. PubMed ID: 30954321
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Estimating the burden of antimicrobial resistance: a systematic literature review.
    Naylor NR; Atun R; Zhu N; Kulasabanathan K; Silva S; Chatterjee A; Knight GM; Robotham JV
    Antimicrob Resist Infect Control; 2018; 7():58. PubMed ID: 29713465
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A Systematic Review of Health Economic Evaluation Studies Using the Patient's Perspective.
    Tai BB; Bae YH; Le QA
    Value Health; 2016; 19(6):903-908. PubMed ID: 27712720
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Economic Evaluations of Remote Patient Monitoring for Chronic Disease: A Systematic Review.
    De Guzman KR; Snoswell CL; Taylor ML; Gray LC; Caffery LJ
    Value Health; 2022 Jun; 25(6):897-913. PubMed ID: 35667780
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The economic evaluation of an antibiotic checklist as antimicrobial stewardship intervention.
    van Daalen FV; Opmeer BC; Prins JM; Geerlings SE; Hulscher MEJL
    J Antimicrob Chemother; 2017 Nov; 72(11):3213-3221. PubMed ID: 28981722
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Managing Uncertainties Due to Limited Evidence in Economic Evaluations of Novel Anti-Tuberculosis Regimens: A Systematic Review.
    Padmasawitri TIA; Saragih SM; Frederix GW; Klungel O; Hövels AM
    Pharmacoecon Open; 2020 Jun; 4(2):223-233. PubMed ID: 31297751
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antimicrobial Stewardship - Do we need it in Pakistan?
    Saleem AF; Pethani A
    J Pak Med Assoc; 2020 Dec; 70(12(B)):2449-2453. PubMed ID: 33475561
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long-term impact of competitive biddings and an antimicrobial stewardship program in a general hospital in Chile.
    Fica A; Valenzuela C; Leiva I; Vergara T; Soto A; Dabanch J; Magunacelaya P
    Rev Med Chil; 2018 Sep; 146(9):968-977. PubMed ID: 30725016
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Economic evaluations in the treatment and evaluation of patients with periodontal disease: A critical review.
    Tay JRH; Ng E; Nair R; Tan ZS; Tan SHX
    J Clin Periodontol; 2021 May; 48(5):679-694. PubMed ID: 33768622
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antimicrobial stewardship programs - cost-minimizing or cost-effective?
    You J
    Expert Opin Pharmacother; 2015 Feb; 16(2):155-7. PubMed ID: 25331093
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.